Analyst Price Targets — TIL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2026 5:18 pm | — | Robert W. Baird | $7.00 | $6.52 | TheFly | Instil Bio downgraded to Neutral from Outperform at Baird |
| September 16, 2024 10:01 am | Jack Allen | Robert W. Baird | $180.00 | $65.58 | StreetInsider | Baird Reiterates Outperform Rating on Instil Bio Inc (TIL) |
| September 16, 2024 6:54 am | Mitchell Kapoor | H.C. Wainwright | $120.00 | $84.52 | StreetInsider | Instil Bio Inc (TIL) PT Raised to $120 at H.C. Wainwright |
| September 12, 2024 7:26 am | Mitchell Kapoor | H.C. Wainwright | $40.00 | $39.19 | StreetInsider | Instil Bio Inc (TIL) PT Raised to $40 at H.C. Wainwright |
| April 12, 2024 2:30 am | Kelly Shi | Jefferies | $11.00 | $11.06 | StreetInsider | Jefferies Downgrades Instil Bio Inc (TIL) to Hold, 'Company Exploring New Avenues Beyond TILs' |
| December 12, 2022 10:44 am | — | Morgan Stanley | $2.00 | $0.84 | Benzinga | Morgan Stanley Maintains Equal-Weight on Instil Bio, Lowers Price Target to $2 |
| June 5, 2022 1:46 pm | Vikram Purohit | Morgan Stanley | $9.00 | $6.01 | TheFly | Instil Bio price target lowered to $9 from $14 at Morgan Stanley |
Latest News for TIL
Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip was attributed to one-off events, not demand weakness. Gross margin was impacted by temporary costs but is expected to improve to 50%+ as internal manufacturing scales and opex reductions take effect.
Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced allowance to proceed from the U.S.…
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update. Recent Highlights Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates Cash position…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TIL.
U.S. House Trading
No House trades found for TIL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.